Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.

摘要: Photodynamic therapy (PDT) is an effective clinical treatment for a number of different cancers. PDT can induce hypoxia and inflammation, pro-angiogenic side effects, which may counteract its angio-occlusive mechanism. The combination with anti-angiogenic drugs offers possibility improved anti-tumour outcome. We used two tumour models to test the effects clinically approved angiostatic tyrosine kinase inhibitors sunitinib, sorafenib axitinib in PDT, compared these results bevacizumab, anti-VEGF antibody, improvement PDT. Best were obtained from low-dose or sorafenib. Molecular analysis by PCR revealed that suppressed VEGFR-2 expression vasculature. Treatment although as monotherapy, did not improve In order vessel normalization was also applied prior absence outcome experiments, well lack increased oxygenation axitinib-treated tumours, suggests vascular occur. current data imply there future certain agents further efficacy photodynamic anti-cancer therapy.